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cation utilization and overall health care service use.
METHODS: A prospective longitudinal cohort study em-
ploying robust multiple regression analyses was con-
ducted over a 2-year post-enrollment period in 762 man-
aged care enrolled diabetic older adults, for whom complete
prescription refill data were available. Patients completed
a comprehensive health risk screen measuring self-re-
ported health perception, falls, lifestyle, depressive symp-
tomatology, and pre-enrollment health care service use at
time of enrollment in the plan. We used the medication
possession ratio and total annual health care charges as
measures of post-enrollment antidiabetic medication and
health care service use. RESULTS: We found that in this
population, annual medication possession rates were
nearly 57% for oral hypoglycemics, as compared to ap-
proximately 40% for both insulin as well as insulin sensi-
tizers. Among antidiabetic medications, only insulin pos-
session decreased across time (P  0.05). Older adults
with increased number of diabetic medications, as well as
reporting to have had falls under utilized all antidiabetic
medications (P  0.05). Patients with increased age and
comorbidity under utilized insulin sensitizers (P  0.001).
Self-reported health status was predictive of total health
care service utilization in this population, but not antidia-
betic medication use. After controlling for the significant
effects of health status, comorbidity severity, and number
of medications, a 10% increase in the use of oral hy-
poglycemics was associated with a 3.5% decrease in total
annual non-prescription related health care charges (P 
0.001). CONCLUSION: There seem to be significant dif-
ferences in utilization patterns of different antidiabetic
medications in this older adult population, with a clear
decrease in health care service use associated with in-
creased utilization of oral hypoglycemics. Improving medi-
cation adherence could potentially reduce avoidable med-
ical costs in similar populations.
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OBJECTIVE: To assess the cost-effectiveness of a new
human dermal replacement (Dermagraft–D) compared with
current practice (CP). METHODS: A Markov model was
developed, to simulate the health status of a cohort of
100 patients with a diabetic foot ulcer, during 52 weeks.
The health states considered are: healed, same site recur-
rence, unhealed not infected, cellulitis, osteomyelitis, am-
putation and death. The set of transition probabilities is
derived directly from the US clinical trial. The costs of
each health state were estimated by a Delphi panel of dia-
betologists (direct costs only in a societal perspective).
RESULTS: The total number or ulcers healed is first ul-
cers healed (D: 76,38; median time to heal—MTH: 14–
15 weeks vs CP: 69,35, MTH: 28–29 weeks) plus recur-
rences which are subsequently healed within the 52-week
period (D: 25,24; MTH 3–4 weeks; CP: 14,29 MTH: 5–6
weeks) are significantly different. The average expected
cost per patient (C/E) with CP for the 52 weeks period
considered is 47,418 French Francs (FF) vs 54,384 FF for
D group (including 18.200 FF for D treatment and
36,184 FF of conventional treatment). Because D heals
more ulcers, the average cost per ulcer healed is lower
(53,522 FF vs 56,687 FF). The incremental cost-effective-
ness ratio of D (C/E) equals 387.84 FF. CONCLU-
SION: Human dermal replacement is cost-effective be-
cause it offers an opportunity to heal ulcers for less than
the price that is already paid by the collectivity, using
standard practice (56,687 FF).
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OBJECTIVE: The CODE-2 study provided costs for pa-
tients with diabetes mellitus type 2 in Germany. The aim
of this analysis is to assess the accuracy of these esti-
mates. METHODS: The German arm of CODE-2 was
based on a representative sample of 809 diabetic patients.
Treatment strategies, resource use and costs were investi-
gated for the year 1998. Patients were grouped in 5 strata
based on their complication status, which was assumed
to be the main cost factor. Rare cost driver groups were
over-represented in order to obtain higher accuracy of es-
timates. For extrapolation on a population level, the re-
sults were weighted according to real prevalence data on
complications estimated in a pre-study. Results were cal-
culated as a weighted average from the mean in each stra-
tum. Because the degree of precision of these estimates
was not measurable with the usual statistical methods,
bootstrap estimates were computed for lower and upper
bounds of 95% confidence intervals taking 10,000 inde-
pendent bootstrap samples. RESULTS: Bootstrap esti-
mates were stable after 10,000 replicate samples. CON-
CLUSION: Bootstrap confidence intervals show a
remarkable accuracy of estimations performed in this
study. So combination of a weighted stratification by cost
factor followed by bootstrapping estimation is an appro-
priate method for analysing the average of highly vari-
able parameters such as costs of diabetes.
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OBJECTIVE: To study the impact of a Medicare policy
change, effective July 1998, extending coverage for glu-
cose test equipment to all diabetics, including those not
using insulin. METHODS: Using a file of 5% of Medi-
care beneficiaries, we identified those with continuous
fee-for-service coverage from 1996-1998 and a diabetes
diagnosis on inpatient or physician claims in 1997. Mon-
itor and test strip use was determined by allowed claims
in the durable medical equipment claim files. RESULTS:
We identified 163,990 diabetic subjects (estimated preva-
lence among Medicare beneficiaries, 14%). Fourteen per-
cent of diabetics were estimated to have used glucose
monitors prior to January 1997; an additional 6.1% had
new monitor claim(s) between January 1997 and Decem-
ber 1998. From July through December 1998, mean
number of new monitor users per month was nearly tri-
ple that observed prior to July 1998. Nearly all of those
beginning monitor use between January 1997 and June
1998 had claim modifiers indicating insulin dependence,
compared to 59% of new users between July and Decem-
ber 1998. The proportion of subjects with test strip or
monitor claims in 1999 did not differ significantly be-
tween those who commenced use prior to July 1998, and
those who did so between July 1998 and December
1998; among new users of monitors, insulin users and
non-users were equally likely to have monitor or strip
claims in 1999. Insulin users had a higher number of
claims per person. CONCLUSIONS: Although extended
coverage increased new glucose monitor use in insulin us-
ers and non-users, overall use by diabetics remained rela-
tively low. New and established users were equally likely
to sustain use in 1999. As new technology becomes avail-
able for glucose monitoring, claims data offer a method
of identifying the potential target population and esti-
mating the likely impact of coverage policy changes on
utilization and costs.
Average
Bootstrapping 95%
confidence level
Total costs per patient and
year [DM] 5,539 5,184–5,894
Total costs for Germany [DM] 21 billion 19,5–22,5 billion
HbA1c 7.84 7.63–8.07
Treatment type [%]
Diet 19.4 16.7–22.1
OAD 53.0 49.6–56.4
Insulin 27.6 24.5–30.7
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OBJECTIVE: To estimate the personal expenditure and
lost earnings borne by individuals as a result of Type 2
Diabetes. METHOD: A postal questionnaire was sent to
a random sample of 750 Type 2 Diabetes patients and
their informal carers at each of 4 UK clinical centres as
part of the T2ARDIS cost of illness survey. The samples
were drawn from registers including patients receiving
only primary care as well as those receiving hospital care.
Personal expenditure data were collected from the ques-
tionnaire. Lost earnings were estimated for working age
respondents who reported that they were not working
full time because of their diabetes or because of the de-
mands of caring for someone with Type 2 Diabetes. Age
and gender specific average earnings were then applied,
adjusted downwards for national unemployment. RE-
SULTS: A total of 1578 patients (52.6%) and 500 regu-
lar informal carers responded to the survey. There was
no significant response bias amongst the patients, based
on checks of non-respondent demographics and treat-
ment regimes. The patients (n  1578) reported average
personal expenditure of £234 per year (SD 1486), but
those with an informal carer (n  500) reported higher
average expenditure at £384 per year (SD 2195). A wide
range of expenditure items was reported but the largest
single category of expenditure was private healthcare and
OTC medication. Carers themselves (n  500) reported
an average of £161 (SD 549) personal expenditure per
year. The lost earnings of patients and carers combined
were estimated at £568 (SD 3463) per patient (n  1578),
and £1441(SD 5620) per patient with a carer (n  500).
CONCLUSION: People with Type 2 Diabetes and their
informal carers incur a substantial economic burden, be-
fore consideration of the impact on their quality of life.
This burden includes significant personal expenditure,
particularly on private healthcare, and significant lost
earnings as a result of the condition.
PDB6
THE FINANCIAL EFFECTS OF INTERFACE 
AGREEMENTS FOR DIABETES MELLITUS: 
SOCIOECONOMIC RELEVANCE OF INTENSIVE 
CONTROLLED INSULIN THERAPY WITH 
INSULIN LISPRO COMPARED TO REGULAR 
HUMAN INSULIN
Kilburg A1, Clouth J2, Daniel D1, Kirchhoff D1, Rychlik R1
1Institute of Empirical Health Economics, Burscheid, Germany; 
2Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: To assess the costs of intensive controlled
therapy with insulin lispro compared to regular human
